Combine 6-8 suppliers into one and simplify life for your study operations teams.
Designing clinical trial participant materials is not about accuracy alone. It also requires understanding how people process and revisit information. As we age, reading patterns often shift. Vaughn X Anthony explores how thoughtful writing and design can help older participants navigate study materials and make study information easier to navigate without sacrificing accuracy or compliance.
Ancillary supplies and equipment are getting much more attention across supply teams, and this is changing how clinical studies are planned and executed. At this spring’s GCSG meeting, the conversations around ownership, definitions, and the global movement of non-drug materials were louder and more consistent than in past years. Delve into the blog for insights from Dan McDonald on why ancillaries are moving from background noise to a real point of focus, and what that shift means for sponsors, CROs, and supply teams.
Corrective and Preventive Actions (CAPAs) are intended to strengthen quality in clinical trials, but too often they become paperwork rather than prevention. What’s missing is the system-level work that actually reduces recurrence. If you’re shaping CAPA processes or strengthening risk management in your organization, this piece offers a clear, practical framework.